tbuckley/cabot-search huggingface dataset:
Annals Story Slam - A Telling Gesture
Authors: Steven K. Herrine
Journal: Annals of Internal Medicine (2017)

Web Exclusives7 February 2017Annals On Being a Doctor Story Slam - A Telling GestureFREESteven K. Herrine, MDSteven K. Herrine, MDFrom Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W17-0023 SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Video. Annals Story Slam - A Telling Gesture "A Telling Gesture," by Steven Herrine, MD (Duration 5:11)Building on the popular Annals feature “On Being a Doctor,” storytellers share stories about the experience of doctoring on video.For more videos from and information on Annals Story Slam, visit go.annals.org/StorySlam. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: From Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.Current Author Address: Steven K. Herrine, MD, Thomas Jefferson University Hospital, Philadelphia, PA; e-mail, steven.[email protected]edu. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 7 February 2017Volume 166, Issue 3Page: SS1 ePublished: 7 February 2017 Issue Published: 7 February 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.Loading ...
Association between tumor stage of first non-metastatic breast cancer and second contralateral breast cancer.
Authors: Akshara Raghavendra, Arup Kumar Sinha, Limin Hsu, Modesto Patangan, Huong T. Le-Petross, Therese Bartholomew Bevers, Debu Tripathy, Isabelle Bedrosian, Carlos Hernando Barcenas
Journal: Journal of Clinical Oncology (2016)

260 Background: Female breast cancer survivors have an average lifetime risk of 4-8% to develop a contralateral breast cancer (CBC).It is unclear if the tumor stage of the first breast cancer is associated with the development of a second CBC. Methods: We performed a retrospective analysis of women who had a presenting diagnosis of non–metastatic breast cancer treated at MD Anderson Cancer Center between January 1997 and December 2013. Demographic, clinical, pathologic and treatment information were obtained from an institutional database. We excluded male patients, those treated outside MD Anderson, patients who underwent bilateral mastectomy, and those with unknown tumor characteristics. The primary endpoint was the development of CBC. The time to CBC was measured from the date of diagnosis of the first breast cancer. Patients who did not develop CBC were censored at death, or if alive, at the most recent follow-up visit. Index tumor stages were categorized as 0, I, II and III. Results: We analyzed 8,770 patients (median follow-up of 5.4 years), among whom 259 (3.0%) developed a CBC. The median follow-up time for stages 0-III was 4.9, 7.2, 5.2 and 3.9 years, respectively. The proportion of patients who developed a CBC by the stage of the index breast cancer was: stage 0: 0/403 (0.0%); stage I: 115/2,143 (5.4%); stage II: 110/4,220 (2.6%); stage III: 34/2,004 (1.7%). The overall median [quartile (Q) 1, Q3] time to the development of CBC was 3.2 (1.2, 6.3) years (stage 0: 0 (0.0, 0.0); stage I: 3.0 (1.2, 6.3); stage II: 4.4 (1.3, 6.9); stage III: 1.6 (0.8, 5.1) years). Conclusions: Patients with stage 0 breast cancer appear to have lower risk of developing a second CBC compared to women presenting with invasive disease. A more detailed analysis of this observation, including incorporation of hormone receptor status and receipt of endocrine therapy, is warranted to determine whether this observation suggests differing biologic risks or treatment/selection bias.
Re-Use of Penicillin after Annulation of Penicillin Allergy in Ambulatory Patients – Long Term Follow-up
Authors: Idit Lachover-Roth, Shoshan Sharon, Yossi Rosman, Keren Meir- Shafrir, Arnon Goldberg, Ronit Confino-Cohen
Journal: Journal of Allergy and Clinical Immunology (2017)
24P Establishment of patient-derived xenografts from malignant pleural effusion using NOG mice
Authors: T. Chijiwa, M. Haraguchi, T. Isagawa, A. Noguchi, M. Katayama, N. Miyao, M. Yoshioka, N. Matsui, Y. Tateishi, H. Suemizu, R. Yamada, Y. Nakamura, D. Imai, D. Komura, H. Katoh, S. Ishikawa, M. Nakamura, Y. Miyagi
Journal: Annals of Oncology (2016)
Age-Adjusted Telomere Length May Predict Treatment-Related Mortality in Children Undergoing Hematopoietic Stem Cell Transplantation
Authors: Pasquale M Barbaro, Peter J. Shaw, Melissa Gabriel, Steven Keogh, Li Zhou, Daniel Catchpole, Loretta Lau, Rebecca Dagg, Hilda A Pickett, Roger R Reddel
Journal: Blood (2015)
Genome-Wide Genotyping of Acute Myeloid Leukemia with t(9;11) Reveals New Recurrent Genomic Alterations,
Authors: Michael W.M. Kühn, Lars Bullinger, Jennifer Edelmann, Jan Krönke, Gröschel Stefan, Frank G. Rücker, Peter Paschka, Verena I. Gaidzik, Karlheinz Holzmann, Richard F. Schlenk, Hartmut Döhner, Konstanze Döhner
Journal: Blood (2011)
Use and Misuse of Opioids in Chronic Pain
Authors: Nora Volkow, Helene Benveniste, A. Thomas McLellan
Journal: Annual Review of Medicine (2017)

The prescribing of opioid analgesics for pain management-particularly for management of chronic noncancer pain (CNCP)-has increased more than fourfold in the United States since the mid-1990s. Yet there is mounting evidence that opioids have only limited effectiveness in the management of CNCP, and the increased availability of prescribed opioids has contributed to upsurges in opioid-related addiction cases and overdose deaths. These concerns have led to critical revisiting and modification of prior pain management practices (e.g., guidelines from the Centers for Disease Control and Prevention), but the much-needed changes in clinical practice will be facilitated by a better understanding of the pharmacology and behavioral effects of opioids that underlie both their therapeutic effects (analgesia) and their adverse effects (addiction and overdose). With these goals in mind, this review first presents an overview of the contemporary problems associated with opioid management of CNCP and the related public health issues of opioid diversion, overdose, and addiction. It then discusses the pharmacology underlying the therapeutic and main adverse effects of opioids and its implications for clinical management of CNCP within the framework of recent clinical guidelines for prescribing opioids in the management of CNCP.
Coinheritance of Alpha-3.7 Deletion and Hb Questembert [131alpha-2 Tct &gt; CCT](Ser131&gt;Pro)] in an African American Patient Results in an Alpha Thalassemia Phenotype
Authors: Asiya Shakir, Betty Pace, Niren Patel, Ferdane Kutlar, Abdullah Kutlar, Afshin Ameri
Journal: Blood (2015)
Id1 and Id3 genes confer poor prognosis in KRAS-mutant (KM) lung adenocarcinoma (LA) patients. Gene silencing reduces metastatic rate to the liver and increases survival
Authors: M. Román, I. Lopez, L. Zubiri, R. Sanchez, D. Salas, I. Gardeazabal, I. Baraibar, M. Santisteban, S. Vicent, I. Gil-Aldea, M. Martinez Aguillo, B. Hernandez, J.M. Lopez-Picazo, A. Gurpide, E. Guruceaga, J.L. Perez-Gracia, M. Collantes, M. Ecay, I. Gil-Bazo
Journal: Annals of Oncology (2016)
A randomized phase III trial of capecitabine with or without irinotecan driven by UGT1A1 in neoadjuvant chemoradiation of locally advanced rectal cancer (CinClare)
Authors: J. Zhu, J. Chen, Y. Zhu, J. Zhou, Y. Zhu, T. Zhang, J. Jia, C. Zhang, X. Wang, Y. Gao, G. Cai, B. Luo, J. Wu, A. Liu, B. Xu, Z. Zhang
Journal: Annals of Oncology (2016)
Correlation between severe infection and breast cancer metastases in the EORTC 10994/BIG 1-00 trial: Investigating innate immunity as a tumor suppressor in breast cancer
Authors: N. Touati, K. Tryfonidis, F. Caramia, H. Bonnefoi, D. Cameron, L. Slaets, B.S. Parker, S. Loi
Journal: Annals of Oncology (2016)
Influence of the Insertion Site on Central Venous Catheter Related Complications in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation, High Dose Therapy or Induction Therapy for Acute Leukemia
Authors: Daniela Heidenreich, Eleonore Muetzel, Sebastian Kreil, Florian Nolte, Melanie Faust, Mohamad Jawhar, Anna Hecht, Wolf-Karsten Hofmann, Stefan A. Klein
Journal: Blood (2015)
Phase II randomized trial of toremifene 120 mg compared with exemestane 25 mg after prior nonsteroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive breast cancer.
Authors: Hirotaka Iwase, Yutaka Yamamoto, Takashi Ishikawa, Yasuo Hozumi, Masahiko Ikeda, Hiroji Iwata, Hiroko Yamashita, Tatsuya Toyama, Takashi Chishima, Izo Kimijima, Mutsuko Ibusuki, Shigehira Saji
Journal: Journal of Clinical Oncology (2012)

105 Background: The non-steroidal aromatase inhibitors (nsAIs) have been mainly employed as adjuvant therapy or as early recurrent treatment for postmenopausal breast cancer with hormone receptor-positive tumor. When its treatment fails, it is unclear which endocrine therapy including selective estrogen receptor modulator (SERM), steroidal AI (sAI), or fulvestrant is the most appropriate. Methods: Open labeled multicenter randomized comparative trial of high-dose toremifene for nsAI resistant breast cancer compared to exmestane (Hi-FAIR ex; registry number UMIN000001841) was performed from Nov 2008 to Oct 2011. Toremifene 120 mg (TOR120) or exemestane 25mg (EXE) was administered once daily. The primary end point was clinical benefit rate (CBR). The secondary end points were objective response rate (ORR), progression-free survival (PFS), overall survival (OS) and toxicity. Results: A total of 91 women were randomly assigned to TOR120 (n=46) or EXE (n=45). Two of 46 cases allocated for TOR120 refused this trial before the administration. There was no difference of patients’ characteristics between both groups. In the analysis as of median 16.9 months for an observation period, TOR120 were superior to EXE in CBR (47.5% vs. 26.7%; p=0.046) and in PFS (Hazard ratio; 0.62, 95% CI; 0.38-0.99, p=0.047). There was, however, no statistical differences in ORR (11.6% vs. 2.2%; p=0.065) and in OS (hazard ratio; 0.57, 95% CI; 0.24-1.34, p=0.19). Both treatments were well-tolerated, with no severe adverse events, although 3 of 44 women treated by TOR120 were stopped in a couple of weeks because of nausea and general fatigue which were thought to be early endocrine-related symptoms. Conclusions: Our data suggested that toremifene 120mg, as a following therapy for postmenopausal metastatic breast cancer who have failed non-steroidal AI treatment, could be potentially useful than steroidal AI.
Decellularized human colorectal cancer matrices polarize macrophages towards an anti-inflammatory phenotype promoting cancer cell invasion via CCL18
Authors: M.L. Pinto, E. Rios, A.C. Silva, S.C. Neves, H.R. Caires, A.T. Pinto, C. Durães, F.A. Carvalho, A.P. Cardoso, N.C. Santos, C.C. Barrias, D.S. Nascimento, P. Pinto-do-Ó, M.A. Barbosa, F. Carneiro, M.J. Oliveira
Journal: Biomaterials (2017)
Whole Exome Sequencing Identifies Potential Defects in Multiple Immunodeficiency-Associated Genes in Individual Patients and Families with Primary Immunodeficiency Diseases
Authors: Ivan Chinn, Lisa R. Forbes, Sarah K. Nicholas, Emily Mace, Zeynep Coban-Akdemir, Nicholas L. Rider, Shalini N. Jhangiani, Wojciech K. Wiszniewski, Richard A. Gibbs, James R. Lupski, Jordan Orange
Journal: Journal of Allergy and Clinical Immunology (2017)
Clinical outcomes and testosterone levels following continuous androgen deprivation (CAD) in patients with relapsing or locally advanced prostate cancer (PC): A post hoc analysis of the ICELAND study
Authors: B. Tombal, E. Cornel, V. Matveev, T.L. Tammela, J. Schraml, W. Warnack, R. Persad, A. Stari, F.G. Veiga, C. Schulman
Journal: Annals of Oncology (2016)
Minimal Residual Disease After the First Cycle of Chemotherapy in Acute Myeloid Leukemia: A Comparative Study of WT1 RQ-PCR and 4-Color Flow Cytometry.
Authors: Carlo Marani, Raffaella Grasso, Nicoletta Colombo, Marino Clavio, Fabio Guolo, Annalisa Kunkl, Livia Giannoni, Giuseppina Fugazza, Roberto Bruzzone, Mario Sessarego, A. M. Carella, Marco Gobbi, Maurizio Miglino
Journal: Blood (2012)
Dupilumab Improves Sense of Smell and Reduces Anosmia Among Patients with Nasal Polyposis and Chronic Sinusitis: Results from a Phase 2a Trial
Authors: Robert M. Naclerio, Daniel L. Hamilos, Berrylin J. Ferguson, Claus Bachert, Peter W. Hellings, Joaquim Mullol, Philippe Gevaert, Donghui Zhang, Asif Khan, Chunpeng Fan, Vijay N. Joish, Nikhil Amin, Gianluca Pirozzi, Neil MH. Graham, Heribert W. Staudinger, Annette Grabher, Leda Mannent
Journal: Journal of Allergy and Clinical Immunology (2017)
Testicular Relapse in Lesser, Standard, and High Risk Patients Treated with Frontline Therapy for Childhood ALL. Pediatric Oncology Group Protocols 9201, 9405, 9605, and 9406.
Authors: Melissa Harrison, Beverly Bell, Allen Chauvenet, Joanne Kurtzberg, Bruce Camitta, Meenakshi Devidas
Journal: Blood (2006)
Surrogate biomarkers of antiangiogenesis in Children's Oncology Group (COG) phase I trials.
Authors: S. Baruchel, B. Wu, R. B. Mokhtari, J. L. Glade Bender, S. G. DuBois, B. C. Widemann, J. R. Park, D. Stempak, C. H. Ahern, B. Weigel
Journal: Journal of Clinical Oncology (2011)

9502
TMIC-04. GLIOBLASTOMA-ASSOCIATED MYELOID CELLS DISPLAY NONPOLARIZED M0 MACROPHAGE PHENOTYPE
Authors: Konrad Gabrusiewicz, Benjamin Rodriguez, Jun Wei, Yuuri Hashimoto, Luke Healy, Sourindra Maiti, Ginu Thomas, Shouhao Zhou, Qianghu Wang, Ahmed Elakkad, Brandon Liebelt, Nasser Yaghi, Ravesanker Ezhilarasan, Neal Huang, Jeffrey Weinberg, Sujit Prabhu, Ganesh Rao, Raymond Sawaya, Lauren Langford, Janet Bruner, Gregory Fuller, Amit Bar-Or, Wei Li, Rivka Colen, Michael Curran, Krishna Bhat, Jack Antel, Laurence Cooper, Erik Sulman, Amy Heimberger
Journal: Neuro-Oncology (2016)

The glioblastoma (GBM) microenvironment is commonly infiltrated with innate immune cells including microglia, macrophages, and myeloid-derived suppressor cells (MDSCs). Presumably these cells assume a tumor-supportive alternatively activated M2 phenotype, but no comprehensive phenotypic and/or genotypic studies have been conducted yet. Flow cytometry analysis was utilized to determine the expression of M1 and M2 markers in the GBM-associated myeloid cells (GAMs). Whole-genome microarray analysis was performed using RNA isolated from GAMs and matched GBM-patient and healthy-donor blood myeloid cells. Nanostring Technology was used to profile immune system- and cancer-related genes in GAMs, matched GBM-patient blood myeloid cells, healthy-donor blood myeloid cells, normal human microglia, and nonpolarized M0 and M1-, M2a-, M2c-polarized macrophages. Gene Set Enrichment Analysis (GSEA) was used to identify hallmarks of biological states or processes in immune cells derived from GBM-patient blood and tissue compared to healthy donors. Among CD11b+ cells, microglia and MDSCs constituted a higher percentage of GAMs compared to macrophages. In contrast, microglia were the most common CD11b+cells isolated from nonmalignant surgical brain samples, with macrophages constituting the remaining contributor to the brain parenchyma. Classical GBMs had significantly higher number of MDSCs than macrophages, while the mesenchymal subtype had more microglia than MDSCs and macrophages. The number of GAMs positively corresponded with the overall tumor size (precisely with edema) but not with overall patient survival. Flow cytometry studies and gene expression profile analysis revealed that GAMs express both anti-tumor M1 and tumor-supportive M2 markers. GSEA identified biological processes in these cells relative to matched blood cells, including signaling by KRAS, TGF-β, and TNF-α, epithelial-mesenchymal transition, angiogenesis, and hypoxia. Unsupervised analysis of gene expression profiles showed that GAMs aligned closely with nonpolarized M0 macrophages. New immunotherapeutic strategies for GBM are needed to redirect nonpolarized M0 GAMs towards the M1 phenotype.
Ecologic Relation between Staphylococcus Aureus and Pseudomonas in a Nursery Population
Authors: I.J. Light, J.M. Sutherland, M.L. Cochran, J. Sutorius
Journal: New England Journal of Medicine (1968)

Abstract The effect of certain nursery procedures on the colonization of newborn infants with Staphylococcus aureus and gram-negative bacilli was examined. During a period of only hexachlorophene handwashing by personnel, 50 per cent of infants were colonized with Staph. aureus at either the nasal or umbilical site. The introduction of hexachlorophene bathing of infants resulted in a decrease in colonization with Staph. aureus to 4 to 6 per cent. The addition of an antibacterial foam to the handwashing procedure resulted in a further small decrease in colonization with Staph. aureus at the nasal site. Concurrent with this decrease was a significant increase in colonization with gram-negative bacilli. A specific inverse relation existed between Staph. aureus and undefined pseudomonas species. This relation can be interpreted as another example of bacterial interference. It is suggested that the spontaneous acquisition of Staph. aureus may prevent the later acquisition of certain gram-negative organisms by ...
267P Irinotecan monotherapy as third line treatment for advanced gastric cancer patients refractory fluoropyrimidine, platinum and taxanes harboring UGT1A1*1/*1. *1/*6 or *1/*28
Authors: N. Sugimoto, T. Yoshinami, T. Yagi, A. Hasegawa, F. Fujisawa, F. Imamura
Journal: Annals of Oncology (2016)
The Impact of an Integrated Antibiotic Allergy Testing Program on Antimicrobial Stewardship: A Multicentre Evaluation
Authors: Jason A. Trubiano, Karen Thursky, Andrew J. Stewardson, Karen Urbancic, Leon J. Worth, Michael Sutherland, Monica A. Slavin, M. Lindsay Grayson, Elizabeth J. Phillips
Journal: Journal of Allergy and Clinical Immunology (2017)
RARE-32. CLINICAL OUTCOMES IN PATIENTS WITH CENTRAL NEUROCYTOMA
Authors: Ugonma Chukwueke, Corey Gill, Tracy Batchelor, Priscilla Brastianos
Journal: Neuro-Oncology (2016)

To describe clinical outcomes in patients with central neurocytoma at a tertiary hospital. Central neurocytomas are uncommon primary tumors that occur in extraventricular or intraventricular locations. We performed a retrospective review of clinical records of 13 patients with central neurocytoma managed at a tertiary hospital from 1997-2015. The median age of diagnosis was 22.8 years (range 18.6 - 60.1). Eleven tumors were intraventricular and two were extraventricular. Headaches were the most common clinical presentation (84.6%). Focal neurologic deficits occurred in 7.7% of patients. Gross total resection was achieved in 53.8% of patients and sub-total resection in 38.5%. Among the population where a MIB-1 index was obtained, 66.7% had an elevated index > 3%. 30.8% of patients had post-operative, focal neurological deficits including hemiparesis. In this population, 23.1% of patients progressed with a median progression-free survival (PFS) of 13.6 months. All patients with progressive disease underwent subsequent resection, followed by proton beam radiation. 76.9% of patients have been recurrence-free with median PFS of 110 months. Central neurocytomas are slow-growing tumors with low rates of recurrence. Genomic characterization of these tumors is needed to identify the molecular features that correlate with recurrence.
Something new in the air: Paying for community-based environmental approaches to asthma prevention and control
Authors: Megan M. Tschudy, Joshua Sharfstein, Elizabeth Matsui, Charles S. Barnes, Stacey Chacker, Rosa Codina, John R. Cohn, Megan Sandel, H. James Wedner
Journal: Journal of Allergy and Clinical Immunology (2017)
“Months, not years”: Impact of clinical discussions of advanced cancer life-expectancy on patient illness understanding.
Authors: Andrew S. Epstein, Holly Gwen Prigerson, Leonard Saltz, Eileen Mary O'Reilly, Manish A. Shah, Paul K Maciejewski
Journal: Journal of Clinical Oncology (2015)

30 Background: Patients’ understanding of their illness often guides best practice, and this is no less true at the end of life. Data showing the influence of patients’ acknowledgment of prognostic discussions on the accuracy of patients’ illness understanding could inform the debate regarding how to engage in these difficult discussions. Methods: To evaluate the effects of recent and past oncologist-patient discussions about prognosis/life-expectancy (P/LE) on changes in advanced cancer patents’ illness understanding (acknowledgement of their illness as 1. terminal; 2. incurable; 3. advance staged; and 4. associated with an estimated life-expectancy in months, not years), 208 patients (with advanced lung or upper gastrointestinal cancers that progressed on 1 chemotherapy regimen, or advanced colorectal cancers that progressed on 2) from Coping with Cancer II, a prospective observational cohort study, were interviewed before and after a visit with their oncologists who discussed scan results regarding potential additional progression. Results: Median time between pre- and post-scan interviews was 38 days. Controlling for potential confounds (i.e., patients’ race) and adjusting for patients’ pre-scan illness understanding, patients who acknowledged ever having discussions of P/LE with their oncologists were more likely to recognize that their disease was incurable (Adjusted Odds Ratio [AOR] = 2.97, p = 0.009) than those who did not. Compared to patients who denied ever having a discussion of P/LE, those who reported having both recent and past discussions of P/LE were more likely to recognize that their disease was at an advanced stage (AOR = 4.88, p = 0.012), and those who reported having only recent discussions, or both recent and past discussions, of P/LE were more likely to estimate their life-expectancy in terms of months as opposed to years (AOR = 10.1, p = 0.050, and AOR = 17.5, p = 0.006, respectively). Conclusions: Advanced cancer patients who acknowledge having discussions of P/LE with their oncologists have a better understanding of the terminal nature of their illnesses as compared to those who do not, and thus may be better prepared to make informed end-of-life care decisions.
The cost-effectiveness of real-time pulmonary artery pressure monitoring in heart failure patients: a European perspective
Authors: Martin R. Cowie, Marcus Simon, Liviu Klein, Praveen Thokala
Journal: European Journal of Heart Failure (2017)

Abstract Aims Heart failure ( HF ) treatment guided by physicians with access to real‐time pressure measurement from a wireless implantable pulmonary artery pressure ( PAP ) sensor ( CardioMEMS ), has previously been shown to reduce HF‐related hospital admissions in the CHAMPION trial. However, uncertainty remains regarding the value of CardioMEMS in European health systems where healthcare costs are significantly lower than in the USA . Methods and results A Markov model was developed to estimate the cost‐effectiveness of PAP ‐guided treatment of HF using the CardioMEMS ™ HF system compared with usual care. Cost‐effectiveness was measured as the incremental cost per quality‐adjusted life year ( QALY ) gained. In the base case analysis over a time horizon of 10 years, PAP ‐guided HF therapy increased cost compared with usual care by £10 916 (€14 030). QALYs per patient for usual care and PAP ‐guided patients were 2.57 and 3.14, respectively, reflecting an increase of 0.57 QALYs with PAP ‐guided treatment. The resultant incremental cost‐effectiveness ratio ( ICER ) is £19 274 (€24 772) per QALY gained. The base case analysis did not include staff time, due to a lack of data concerning this variable. Running the model with estimated staff time included resulted in an increased ICER of between £22 342 and £25 464 per QALY gained (€28 709–32 721). Conclusion The analysis indicates that integrating wireless PAP monitoring into the management of UK HF patients is likely to be a cost‐effective addition to the HF treatment pathway for appropriate patients.